Methods for treating cancer resistant to erbb therapeutics

Abstract

Provided herein are methods for treating cancer that is resistant to treatment with an anti-ErbB therapeutic agent and which is associated with an activating MET gene mutation or a MET gene amplification. The methods involve administering to a subject a combination of an anti-ErbB therapeutic and an anti-MET therapeutic. Also provided are methods for reducing ErbB mediated signaling or PI3 kinase mediated signaling in a cancer cell.

1 - 62 . (canceled) 
     
     
         63 . A method for identifying a subject as a candidate for treatment with an anti-ErbB therapeutic and an anti-MET therapeutic, wherein said subject has been treated with an anti-ErbB therapeutic and suffers from cancer that has acquired resistance to said anti-ErbB therapeutic, comprising detecting a MET activating mutation or MET gene amplification in a cancer cell from said subject. 
     
     
         64 . (canceled) 
     
     
         65 . A method for identifying a subject who is being treated with an anti-ErbB therapeutic and who is at risk for acquiring resistance to said anti-ErbB therapeutic, comprising detecting the presence of a MET activating mutation or a MET gene amplification in a cancer cell from said subject, wherein the presence of said MET activating mutation or MET gene amplification indicates a risk for acquiring said resistance. 
     
     
         66 - 85 . (canceled) 
     
     
         86 . The method of  claim 63 , wherein the cancer is lung cancer, brain cancer, breast cancer, head and neck cancer, colon cancer, ovarian cancer, gastric cancer, or pancreatic cancer. 
     
     
         87 . The method of  claim 86 , wherein the cancer is non-small cell lung cancer (NSCLC). 
     
     
         88 . The method of  claim 63 , wherein the subject has an EGFR, ErbB2, ErbB3, or ErbB4 activating mutation or gene amplification. 
     
     
         89 . The method of  claim 88 , wherein the subject has an EGFR activating mutation or an EGFR gene amplification. 
     
     
         90 . The method of  claim 63 , wherein the cancer is resistant to treatment with one or more of the following anti-ErbB therapeutics: an anti-EGFR therapeutic, an anti-ErbB2 therapeutic, an anti-ErbB3 therapeutic, or an anti-ErbB4 therapeutic. 
     
     
         91 . The method of  claim 63 , wherein the cancer is resistant to treatment with one or more of the following anti-ErbB therapeutics: a small molecule therapeutic, a nucleic acid therapeutic, or a protein therapeutic. 
     
     
         92 . The method of  claim 91 , wherein the cancer is resistant to treatment with an anti-ErbB antibody. 
     
     
         93 . The method of  claim 91 , wherein the cancer is resistant to treatment with an ErbB kinase inhibitor. 
     
     
         94 . The method of  claim 91 , wherein the cancer is resistant to treatment with an EGFR kinase inhibitor. 
     
     
         95 . The method of  claim 65 , wherein the subject is suffering from cancer. 
     
     
         96 . The method of  claim 95 , wherein the cancer is lung cancer, brain cancer, breast cancer, head and neck cancer, colon cancer, ovarian cancer, gastric cancer, or pancreatic cancer. 
     
     
         97 . The method of  claim 95 , wherein the cancer is non-small cell lung cancer (NSCLC). 
     
     
         98 . The method of  claim 65 , wherein the subject has an EGFR, ErbB2, ErbB3, or ErbB4 activating mutation or gene amplification. 
     
     
         99 . The method of  claim 98 , wherein the subject has an EGFR activating mutation or an EGFR gene amplification. 
     
     
         100 . The method of  claim 65 , wherein the subject is being treated with one or more of the following anti-ErbB therapeutics: an anti-EGFR therapeutic, an anti-ErbB2 therapeutic, an anti-ErbB3 therapeutic, or an anti-ErbB4 therapeutic. 
     
     
         101 . The method of  claim 65 , wherein the subject is being treated with one or more of the following anti-ErbB therapeutics: a small molecule therapeutic, a nucleic acid therapeutic, or a protein therapeutic. 
     
     
         102 . The method of  claim 101 , wherein the subject is being treated with an anti-ErbB antibody. 
     
     
         103 . The method of  claim 101 , wherein the subject is being treated with an ErbB kinase inhibitor. 
     
     
         104 . The method of  claim 101 , wherein the subject is being treated with an EGFR kinase inhibitor.